​

MapLight Therapeutics (MPLT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MPLT Stock Forecast

MapLight Therapeutics (MPLT) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $35.10, with a high of $52.00 and a low of $21.00. This represents a 164.31% increase from the last price of $13.28.

MPLT Stock Rating

MapLight Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

MPLT Price Target Upside V Benchmarks

TypeNameUpside
StockMapLight Therapeutics164.31%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts91419
Avg Price Target$34.67$37.50$36.53
Last Closing Price$13.28$13.28$13.28
Upside/Downside161.07%182.38%175.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 261121--14
Jul, 26210---12
Jun, 2629---11
May, 2625---7
Apr, 2614---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 28, 2026Adam VogelCraig-Hallum$25.00$10.21144.86%88.25%
Jul 28, 2026Sumant KulkamiCanaccord Genuity$24.00$9.91142.18%80.72%
Jul 28, 2026Morgan Stanley$21.00$9.91111.91%58.13%
Jul 28, 2026Raghuram SelvarajuH.C. Wainwright$26.00$9.91162.36%95.78%
Jul 27, 2026Rudy LiWolfe Research$30.00$9.91202.72%125.90%
Jul 24, 2026Sumant KulkarniCanaccord Genuity$43.00$35.2322.06%223.80%
Jul 21, 2026UBS$52.00$35.9944.48%291.57%
Jul 20, 2026BMO Capital$46.00$35.9927.81%246.39%
Jul 10, 2026Needham$45.00$39.8013.07%238.86%
Jun 24, 2026Raymond James$46.00$30.6550.08%246.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 28, 2026Craig-HallumBuyBuyhold
Jul 28, 2026H.C. WainwrightBuyBuyhold
Jul 27, 2026Wolfe ResearchOutperformOutperformhold
Jul 27, 2026JefferiesBuyBuyhold
Jul 21, 2026UBSBuyBuyhold
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 10, 2026NeedhamBuyBuyhold
Jun 24, 2026Raymond JamesStrong Buyinitialise
Jun 22, 2026BenchmarkBuyBuyhold
May 26, 2026UBSBuyinitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-5.15$-3.65
High Forecast$-3.50$-2.78
Low Forecast$-6.47$-4.40
Surprise %--

Revenue Forecast

Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-300M $-260M $-220M $-180M $-140M $-100M Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-213.36M$-151.22M
High Forecast$-145.00M$-115.17M
Low Forecast$-268.05M$-182.29M
Surprise %--

MPLT Forecast FAQ

Is MapLight Therapeutics stock a buy?

MapLight Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MapLight Therapeutics is a favorable investment for most analysts.

What is MapLight Therapeutics's price target?

MapLight Therapeutics's price target, set by 7 Wall Street analysts, averages $35.1 over the next 12 months. The price target range spans from $21 at the low end to $52 at the high end, suggesting a potential 164.31% change from the previous closing price of $13.28.

How does MapLight Therapeutics stock forecast compare to its benchmarks?

MapLight Therapeutics's stock forecast shows a 164.31% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MapLight Therapeutics over the past three months?

  • August 2026: 7.14% Strong Buy, 85.71% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MapLight Therapeutics’s EPS forecast?

MapLight Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.15, marking a 0% decrease from the reported - in 2024. Estimates for the following years are.

What is MapLight Therapeutics’s revenue forecast?

MapLight Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for.

What is MapLight Therapeutics’s net income forecast?

MapLight Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-213M, representing a 0% decrease from the reported - in 2024. Projections indicate .